Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01644253 2021-05-20

Phase 1b Safety and Efficacy Study of TRU-016

Phase 1 Terminated

87 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Peripheral

NCT02242045 2021-03-19

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Phase 1 Completed

6 enrolled 14 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Completed

241 enrolled 31 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02538614 2020-11-25

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

Phase 1 Terminated

2 enrolled 5 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02779283 2020-05-26

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Phase 1 Completed

7 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02603445 2020-02-24

Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

Phase 1 Completed

20 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Mantle-Cell

NCT03349346 2018-12-11

Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

Phase 1 Withdrawn

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01644799 2018-01-30

Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma

Phase 1 Completed

8 enrolled

Lymphoid

Lymphoma, Follicular

NCT01838434 2018-01-30

Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 1 Completed

106 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT00710528 2012-08-31

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Phase 1 Completed

192 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Clinical Trials

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1b Safety and Efficacy Study of TRU-016

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma

Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies